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Abstract
Background: Improvement in cardiac function has been demonstrated after thyrox-
ine treatment in humans with hypothyroidism using the myocardial performance
index (MPI). Cardiac changes after thyroxine supplementation are poorly docu-
mented in dogs with spontaneous hypothyroidism and comparison with clinically
healthy dogs is lacking.
Objectives: To evaluate the electrical activity and mechanical function of the heart in
dogs with primary hypothyroidism at baseline (T0) and after thyroxine supplementa-
tion (T60).
Animals: Forty client-owned dogs with hypothyroidism and 20 clinically healthy dogs.
Methods: Prospective cohort study. Selected electrocardiographic and echocardio-
graphic variables, including the MPI, were measured in all dogs at T0 and in 30 hypo-
thyroid dogs at T60.
Results: Hypothyroid dogs had significantly decreased median or mean heart rate
(HR), P wave amplitude, and R wave amplitude (P = .04, P = .002, and P = .003,
respectively) and E-point-to-septal separation normalized to body weight (EPSSn)
and trans-mitral E wave velocity (E max; P < .001 and P = .025, respectively) at T0
compared to control dogs. At T60, significantly increased median or mean HR,
P wave amplitude, fractional shortening, and E max (P < .001, P = .004, P = .002,
and P = .009, respectively) and significantly decreased left ventricular end-diastolic
volume index, and normalized systolic diameter and EPSSn (P = .03, P = .03, and
P = .001, respectively) were found.
Abbreviations: 2D, 2-dimensional; Ao, aortic root diameter; bpm, beats per minute; BW, body weight; cTSH, canine thyrotropin hormone; DCM, dilated cardiomyopathy; EF, ejection fraction;
EPSS, E point-to-septal separation; EPSSn, E point-to-septal separation normalized for body weight; FS, fractional shortening; HR, heart rate; LA, left atrial diameter; LA/Ao, left atrium to aortic
root diameter ratio; LVDD, left ventricular diastolic diameter; LVDDn, left ventricular diastolic diameter normalized for body weight; LVDS, left ventricular diameter in systole; LVDSn, left
ventricular diameter in systole normalized for body weight; MEA, mean electrical axis; MMVD, myxomatous mitral valve disease; MPI, myocardial performance index; rhTSH, recombinant human
TSH; TT4, total thyroxine.
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Conclusions and Clinical Importance: Hypothyroidism in dogs induces mild and
reversible changes of electromechanical cardiac function. The MPI does not have
clinical importance in identifying cardiac dysfunction in affected dogs.
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1 | INTRODUCTION
Acquired primary hypothyroidism is a common thyroid disorder in dogs
that may cause decreased metabolic rate and dysfunction of almost every
organ in the body. The most commonly reported clinical manifestations of
primary hypothyroidism in dogs include dermatologic signs as well as
reproductive, neurological, and cardiovascular abnormalities.1,2 In particu-
lar, retrospective clinical and experimental studies reported changes of
both cardiac electrical andmechanical functions in dogs with spontaneous
and induced thyroid hormone deficiency.3-13 Reported ECG abnormalities
in hypothyroid dogs include cardiac arrhythmias, such as sinus
bradycardia,7,8 atrial fibrillation,4-6,10 and atrioventricular blocks,7,9,12,14
decreasedRwave amplitude,9,10,12,14 and decreased amplitude or inverted
T wave.10 Partial response to thyroxine treatment with normalization of
ECG changes was reported in some dogs,6-10 and conversion of atrial
fibrillation to sinus rhythm was observed in a dog treated solely with
thyroxine.3
Previous echocardiographic studies in dogs with hypothyroidism
have been predominantly focused on evaluation of left ventricular
(LV) systolic cardiac function. Echocardiographic changes observed in
dogs with spontaneous or experimentally induced hypothyroidism
include increased left ventricular diameter in systole (LVDS) and dias-
tole (LVDD),5,9 decreased LV fractional shortening (FS),3,5 prolonged
pre-ejection period, and decreased velocity of circumferential fiber
shortening.9 All of these alterations might mimic a familiar form of pri-
mary cardiomyopathy such as dilated cardiomyopathy (DCM).15 Thus,
it was previously thought that hypothyroidism-induced cardiomyopa-
thy should be considered a differential diagnosis for DCM in dogs.15
However, LV systolic function and time intervals should improve in
dogs with hypothyroid-induced cardiac changes when appropriate
hormone replacement treatment has been established.16
In humans, both systolic and diastolic cardiac function can be
influenced by thyroid hormones,17 and the myocardial performance index
(MPI), defined as the sum of isovolumetric contraction time plus relaxa-
tion time divided by ejection time, has been proposed as a useful marker
of combined systolic and diastolic cardiac function.18,19 Measurement of
MPI in human patients with hypothyroidism showed deterioration of car-
diac function that was reversible after treatment with thyroxine.17,20 No
study has prospectively investigated the effects of naturally occurring
hypothyroidism on both systolic and diastolic function using the MPI in
dogs. Furthermore, previous studies on cardiac dysfunction in dogs with
hypothyroidism were carried out without the use of a control group of
clinically healthy dogs. Thus, we evaluated cardiac electrical activity and
mechanical function, including measurement of MPI, in euthyroid dogs
and dogs with primary hypothyroidism before and after thyroxine
supplementation.
2 | MATERIALS AND METHODS
2.1 | Animals
Client-owned dogs presented to 2 veterinary teaching hospitals and
with a final diagnosis of primary hypothyroidism were prospectively
included in the study. After the owner signed a written consent form,
each dog underwent physical examination, ECG, echocardiographic
examination, and blood sampling for CBC and serum biochemical pro-
file. Dogs were considered hypothyroid if they showed consistent clini-
cal signs of hypothyroidism (eg, dermatological abnormalities, lethargy,
asthenia, exercise intolerance, cold intolerance, obesity, weight gain),
serum total thyroxine (TT4), and canine thyrotropin hormone (cTSH)
concentrations below and above the reference range, respectively (ie,
TT4 <0.93 μg/dL and cTSH >0.5 ng/mL). In dogs with serum TT4 con-
centration below the reference range and normal serum cTSH concen-
tration, a recombinant human TSH (rhTSH; Thyrogen, Genzyme Corp,
Haverhill, Suffolk, UK) stimulation test was performed. These dogs were
enrolled if both the prestimulation and poststimulation TT4 concentration
were below the reference range (ie, TT4 <0.93 μg/dL). Dogs that had
received thyroid hormone replacement treatment within the previous
8 weeks were excluded. Dogs with concurrent endocrine disorders (eg,
diabetes mellitus, hyperadrenocorticism, hypoadrenocorticism), chronic
renal failure, or chronic hepatic failure alsowere excluded.
After cardiac evaluation, the hypothyroid dogs were started on
treatment with levothyroxine PO as a liquid formulation (Leventa; Inter-
vet Inc, Millsboro, Delaware; starting dosage 20 μg/kg q24h) or tablets
(Canitroid; Eurovet Animal Health BV, Handelsweg, The Netherlands;
starting dosage 10-15 μg/kg q12h). Reevaluations were performed at
approximately 30 and 60 days from treatment initiation and included
clinical history, physical examination, and evaluation of serum TT4 con-
centration, measured 4-6 hours after administration of levothyroxine. If
necessary, the levothyroxine dose then was adjusted. Treatment was
considered appropriate if serum TT4 concentration was within or mildly
above the reference range. At the time of reevaluation, after approxi-
mately 2 months of treatment (T60), cardiac evaluation was repeated,
assuming that thyroid hormone replace treatment was appropriate.
A control population of 20 clinically healthy dogs also was
enrolled. They were recruited from the patients of the 2 hospitals
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presented for periodic routine visits or for evaluation before an elec-
tive procedure. Dogs were considered healthy on the basis of clinical
history and normal results of physical examination, CBC, and serum
biochemical profile, including serum TT4 and cTSH concentrations (ie,
serum TT4 and cTSH >0.93 μg/dL and <0.5 mg/mL, respectively).
Moreover, these animals were considered to have normal cardiovas-
cular health if results of echocardiographic examination were within
normal limits and no rhythm disturbance (other than sinus arrhythmia
or sinus tachycardia) was observed on ECG.
2.2 | Analytical procedures and thyroid evaluation
Serum cTSH concentrations were measured by use of a solid-part,
2-site chemiluminescent enzyme immunometric assay (IMMULITE
1000 Canine TSH; Diagnostic Products Corporation, Los Angeles,
California).21 The intra-assay coefficients of variation were 5.0%, 4%,
and 3.8% at TSH concentrations of 0.20, 0.50, and 2.6 ng/mL, respec-
tively. The interassay coefficients of variation were 6.3% and 8.2%
at TSH concentrations of 0.16 and 2.8 ng/mL, respectively. The sensi-
tivity of the assay was 0.03 ng/mL. The upper limit of the reference
range was 0.5 ng/mL. Serum TT4 concentrations were determined
using a homologous solid-phase, chemiluminescent enzyme immuno-
assay (IMMULITE 1000 Canine total T4, Diagnostic Products Corpo-
ration). The intra-assay and interassay coefficients of variation were
3.9%-10.8% and 5.2%-13.8%, respectively. The sensitivity of the assay
was 0.5 μg/dL. The reference range for TT4 was 0.93-2.87 μg/dL. To
perform the rhTSH-stimulation test, serum TT4 was measured before
and 6 hours after the IV administration of recombinant human TSHc at a
dose of 75 μg per dog.22
2.3 | Cardiac evaluation
A complete cardiac evaluation including physical examination, 6 lead
standard ECG, and trans-thoracic 2-dimensional (2D), M-mode, and
echo-Doppler echocardiogram was performed at T0 in all dogs and at
T60 in hypothyroid dogs.
Each ECG examination was performed with the dogs placed in the
right lateral recumbency using dedicated devices (Archiwin, Esaote S.p.
A., Firenze, Italy; Cube ECG, Cardioline S.p.A., Caverano, Italy; TouchECG
HD, Cardioline S.p.A). Two-minute recordings were acquired to detect
the presence of rhythm disturbances. Electrocardiographic measure-
ments were performed by analyzing a 10-second strip, using a ruler.
Intervals and wave amplitude were obtained as multiple of 10 ms and
0.1 mV, respectively. Variables analyzed included cardiac rhythm (eg,
normal sinus rhythm, sinus arrhythmia, pathological arrhythmias), heart
rate (HR) in beats per minute (bpm) calculated by determining the num-
ber of QRS complexes in a 3-second interval and multiplying this number
by 20 (reference range, 60-160 bpm),23 amplitude and duration of the P
wave, PQ-interval duration, R wave amplitude and duration of the QRS
complex, duration of the QT interval corrected for HR according to the
logarithmic formula (QT interval corrected = log600 × QT/logRR),24 and
mean electrical axis (MEA) of the QRS complex calculated using the fol-
lowing equation: MEA = arctan (Iamp, aVFamp) × 180/π.25
Echocardiographic images were obtained in awake animals using
ultrasound units (CX50, Philips, Eindhoven, The Netherlands; iE33
ultrasound system, Philips Healthcare, Monza, Italy) equipped with
1-5 or 3-8 MHz phased-array transducers and simultaneous ECG
trace recording, according to previously published standards.26 An
M-mode interrogation of the LV was performed from the right par-
asternal short-axis view at the level of the chordae tendineae, and
measurements were obtained using the leading edge-to-leading edge
method.27
The LVDD and LVDS were indexed to the body weight (BW)
according to Cornell's method28 to obtain their normalized measure-
ments (LVDDn and LVDSn, respectively). The LV FS was calculated
according to the formula: FS = [(LVDD − LVDS)/LVDD] × 100. The
mitral valve E point-to-septal separation (EPSS) was measured from
M-mode images obtained from the short-axis view at the level of themitral
valve, as previously described in dogs.29 Because EPSS is a linear dimen-
sion, mildly influenced by the weight of the animal, the absolute value then
was indexed to BW (EPSSn) using the formula: EPSSn = (EPSS/BW1/3).28,30
Left atrial (LA) and aortic root (Ao) diameters were measured using a 2D
method from the right parasternal short-axis view at the heart base level in
early diastole, and their ratio (LA/Ao) was calculated.31 End-diastolic and
end-systolic volumes of the LVwere calculated from images obtained from
the right parasternal 4-chamber long-axis view by the Simpson method of
discs and then indexed to body surface area. The LV ejection fraction
(EF) was obtained using the equation: EF = ([end-diastolic volume − end-
systolic volume]/end-diastolic volume) × 100.
Aortic flow was interrogated by pulsed-wave Doppler from the
subcostal window and peak velocity was recorded. Transmitral flow
was interrogated from the left apical 4-chamber view and peak veloci-
ties of the early diastolic (E) and late diastolic (A) waves were
recorded. Spectral Doppler interrogation of LV inflow and outflow
tracings was obtained from a left apical 5-chamber view and the sys-
tolic times were measured. The LV MPI was calculated according to
the formula: MPI = (isovolumetric contraction time + isovolumetric
relaxation time)/LV ejection time.32
Each echocardiographic and echo-Doppler variable was measured
3 times, and the averaged value was used for statistical analysis.
Dogs enrolled in the control group were considered to have a nor-
mal echocardiographic examination if no clinically relevant valvular
insufficiency was noted on color Doppler examination, no congenital
abnormalities or signs of pulmonary hypertension were detected, and
LVDDn, LVDSn, and LA/Ao were within normal ranges (ie, ≤1.8, <1.3
and <1.6, respectively).28,31
Each ECG and echocardiographic examination was reviewed
by a board-certified cardiologist (M.B.T.) who performed all of the
measurements.
2.4 | Statistical analysis
All data were tested for their distribution using a D'Agostino-Pearson nor-
mality test. Normally distributed data are reported as mean ± standard
deviation, and nonnormally distributed data are reported as median and
range (minimum andmaximum).
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Continuous variables were compared between hypothyroid and
control dogs using an unpaired Student's t test or a Mann-Whitney
U test, whereas comparison between hypothyroid dogs before and
after treatment was carried out using a paired Student's t test or a
Wilcoxon signed rank test. Descriptive categorical data were com-
pared using a Fisher's exact test.
Statistical analysis was conducted using commercially available
programs (Microsoft Excel; Microsoft Office 2011, Microsoft Corpo-
ration, Bellevue, Washington; Prism 5, GraphPad Software Inc, San
Diego, California). A value of P < .05 was considered significant.
3 | RESULTS
3.1 | Animals
Forty recently diagnosed hypothyroid dogs were recruited. Breeds
included 13 mixed breeds, 3 Maremma Sheepdogs and Irish Setters,
2 Italian Hounds, Labrador Retrievers, Doberman Pinschers, and Lagotto
Romagnolo, and 13 dogs of other breeds represented by 1 dog each.
There were 19 intact males and 21 females (11/21 were spayed
females), with a median age of 5.1 years (range, 3-10 years) and BW of
28 ± 13 kg. The control group of healthy dogs included 7 mixed breeds,
2 Labrador Retrievers, Golden Retrievers, Cocker Spaniels, and American
Staffordshire Terriers, and 4 dogs of other breeds represented by 1 dog
each. This control group included 7 males (2/7 were castrated males) and
13 females (4/13 were spayed females) with a median age of 5.4 years
(range, 2-14 years) and BW of 26 ± 8 kg. No significant differences in
distribution of sex, age, and BW were observed between the 2 groups.
The most common clinical signs in the hypothyroid dogs were dermato-
logical abnormalities (74%), asthenia or exercise intolerance (56%), leth-
argy (59%), depression (54%), and weight gain (49%). At the time of
diagnosis, the median hematocrit was 37.5% (range, 28.5-59.6%), and
the hematocrit was mildly below the reference range (37.0-55.0%)
in 16 of 40 dogs (40%). The mean cholesterol concentration was
529 ± 252 mg/dL, and 27 of 40 dogs (67%) had cholesterol concen-
trations above the reference range (140-350 mg/dL). The median
serum concentration of TT4 in hypothyroid dogs was 0.5 μg/dL
(range, 0.5-0.7 μg/dL) because many dogs had TT4 concentration at
the lower limit of detection of the test. Their median cTSH concentra-
tion was 0.78 ng/mL (range, 0.06-11.9 ng/mL), and 34 (85%) of these
dogs had increased serum cTSH concentration. The rhTSH stimulation
test was performed on 13 of 40 hypothyroid dogs (32.5%). The
median pre-stimulation and post-stimulation TT4 concentrations of
these dogs were 0.5 μg/dL (range, 0.5-0.7 μg/dL) and 0.5 μg/dL (range,
0.5-0.54 μg/dL), respectively. Table 1 presents clinical and baseline
hormonal data.
Thirty of the 40 hypothyroid dogs (75%) from the initial study group
completed the study and were reevaluated (T60) after a median time of
70 days (range, 49-166 days) from the beginning of levothyroxine sup-
plementation. Of the remaining 10 animals, 9 dogs were lost to follow-
up and 1 dog died spontaneously with clinical signs of intracranial
disease. At reevaluation at T60, all dogs showed general improvement of
clinical signs. Almost all dogs showed improvement in general metabolic
signs, including 21 of 22 dogs, 23 of 23 dogs, and 20 of 21 dogs showing
asthenia, lethargy, and depression, respectively; 20 of 39 dogs (51%)
showed a decrease in BW; and 22 of 29 dogs with dermatologic abnor-
malities (76%) showed complete resolution or marked improvement of
skin and hair coat alterations. The median TT4 concentration at T60 was
3.19 μg/dL (range, 0.93-9.71 μg/dL). In 21 of 30 dogs (70%), cTSH
concentration was reevaluated and median cTSH concentration was
0.11 ng/mL (range, 0.03-0.38 ng/mL). Eighteen of these 21 dogs
(86%) had high cTSH concentrations at T0, which returned into the
reference range at the time of reevaluation; the other 3 of 21 dogs
(14%) had cTSH concentrations within the reference range at T0 that
remained within the reference range at the time of reevaluation.
3.2 | ECG and echocardiographic data
Electrocardiographic and echocardiographic data at T0 of control dogs
and dogs with hypothyroidism are summarized in Table 2. Regarding
the ECG variables, only 1 hypothyroid dog (2.5%) and 1 control dog
had HR <60 bpm and sinus tachycardia (ie, HR = 200 bpm), respec-
tively, without other cardiac arrhythmias. One hypothyroid dog had
complete right bundle branch block with QRS complex duration of
100 milliseconds and MEA of the QRS of −99 that persisted at T60.
The median HR of hypothyroid dogs (80 bpm; range, 50-160 bpm) was
significantly lower compared to that of control dogs (100 bpm; range,
80-200 bpm; P = .04). Furthermore, hypothyroid dogs had significantly
lower median P-wave amplitude (0.15 mV; range, 0.05-0.35 mV) and
mean R wave amplitude (1.00 ± 0.45 mV), and significantly different
median MEA QRS (61; range, −99 − +96) compared to those of con-
trol dogs (0.20 mV; range, 0.10-0.40 mV, P = .002; 1.48 ± 0.76 mV,
P = .003; 79; range, 45-90; P < .001, respectively). Regarding echocar-
diographic variables, the median EPSSn (2.29; range, 0.48-7.1) was signif-
icantly higher in hypothyroid dogs compared to that of control dogs
(1.27; range, 0.41-2.32; P < .001). Furthermore, a significantly lower
mean E wave velocity (60 ± 15 cm/s) was found in hypothyroid dogs
compared to that of control dogs (70 ± 18 cm/s; P = .02).
Comparisons between ECG and echocardiographic variables
obtained at T0 and T60 in 30 hypothyroid dogs are summarized in
Table 3. After supplementation with levothyroxine, dogs with
TABLE 1 Descriptive data obtained from 60 dogs with
(hypothyroid T0) and without (control g) hypothyroidism
Variable Hypothyroid T0 Control group P value
Number of dogs 40 20 NA
Sex (male/female) 19/21 7/13 .42
Age (y) 5.1 (3–10) 5.4 (2–14) .13
Body weight (kg) 28 ± 13 26 ± 8 .60
TT4 (μg/dL) 0.5 (0.5–0.7) 1.3 (1-2.3) <.001
cTSH (ng/mL) 0.78 (0.06-11.9) 0.13 (0.03-0.48) <.001
Note: Normally and nonnormally distributed data are expressed as mean
± standard deviation and median and range (minimum–maximum),
respectively.
Abbreviations: cTSH, canine thyrotrophin hormone; TT4, serum total
thyroxine.
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hypothyroidism showed significantly increased HR (P < .001) and P-wave
amplitude (P = .009) on ECG tracings, significantly decreased LVDSn
(P = .04) and EPSSn (P = .001), and significantly increased FS (P < .001)
and E- and A-wave velocity (P = .02, and P = .003, respectively) on echo-
cardiography. Regarding echocardiographic indices of LA and LV dimen-
sion, 5 hypothyroid dogs had LA/Ao ≥1.6 at T0 that remained increased
in only 2 of them at T60; 5 dogs had LVDDn at the upper limit of nor-
mality (1.8) at T0, but all dogs had a LVDDn ≤1.7 at T60; and, 2 dogs had
LVDSn of 1.4 at T0 and only 1 dog had LVDSn equal to 1.3 at T60. The
MPI did not differ between control dogs (0.54 ± 0.20) and hypothyroid
dogs at T0 (0.57 ± 0.23; P = .63) and between 30 hypothyroid dogs at
T0 (0.56 ± 0.24) and T60 (0.55 ± 0.16; P = .82).
4 | DISCUSSION
We evaluated the effects of hypothyroidism on cardiac electric activity
and mechanical function before and after levothyroxine supplementa-
tion. Evaluation included measurement of MPI, an echocardiographic
TABLE 2 Electrocardiographic and echocardiographic variables
from 60 dogs with (hypothyroid T0) and without (control group)
hypothyroidism at the time of diagnosis
Hypothyroid T0 Control group
Variable (n = 40) (n = 20) P value
Electrocardiography
HR (bpm) 80 (50–160) 100 (80–200) .04
P-wave
amplitude (mV)
0.15 (0.05–0.35) 0.20 (0.10-0.40) .002
P-wave
duration (ms)
40 (30-50) 40 (30-50) .91
PQ (ms) 100 (70-140) 100 (40-130) .98
QRS (ms) 60 (30-100) 70 (60-81) .10
R-wave
amplitude
(mV)
1 ± 0.45 1.48 ± 0.76 .003
MEA QRS () 61 (−99 to 96) 79 (45-90) <.001
QTc (ms) 201 ± 18 203 ± 12 .80
Echocardiography
LA/Ao 1.3 (1.0-2.6) 1.3 (0.9-1.5) .63
LVDDn 1.5 ± 0.2 1.5 ± 0.1 .59
LVDSn 1.1 (0.6-1.6) 1.1 (0.8-1.2) .93
FS (%) 26 ± 9 25 ± 7 .66
EPSSn 2.29 (0.48-7.1) 1.27 (0.41-2.32) <.001
E-wave velocity
(cm/s)
60 ± 15 70 ± 18 .02
A-wave velocity
(cm/s)
49 ± 16 54 ± 14 .21
MPI 0.57 ± 0.23 0.54 ± 0.20 .63
EDVi (mL/m2) 65 (28-101) 71 (42-88) .99
ESVi (mL/m2) 36 ± 13 33 ± 9 .44
EF (%) 48 ± 11 50 ± 13 .51
Note: Normally and not normally distributed data are expressed as mean
± standard deviation and median and range (minimum–maximum),
respectively. Values with statistically significant difference are indicated
in bold.
Abbreviations: EDVi, end diastolic volume indexed to body surface
area; EF, ejection fraction; EPSSn, E-point-to-septal separation
normalized to body weight; ESVi, end systolic volume indexed to body
surface area; FS, fractional shortening; HR, heart rate; LA/Ao, left atrial
to aortic ratio; LVDDn, left ventricular diastolic diameter normalized to
body weight; LVDSn, left ventricular systolic diameter normalized to
body weight; MEA, mean electrical axis; MPI, myocardial performance
index; QTc, QT interval corrected for heart rate.
TABLE 3 Electrocardiographic and echocardiographic variables
from 30 dogs with hypothyroidism before (hypothyroid T0) and after
treatment with levothyroxine (hypothyroid T60)
Variable Hypothyroid T0 Hypothyroid T60 P value
Electrocardiography
HR (bpm) 80 (50–160) 120 (67-180) <.001
P-wave
amplitude (mV)
0.15 (0.05-0.35) 0.20 (0.10-0.45) .004
P-wave
duration (ms)
40 (30-50) 40 (0.15-50) .09
PQ (ms) 100 (80-140) 98 (30-160) .06
QRS (ms) 63 (30–100) 65 (40-90) .67
R-wave
amplitude (mV)
1.04 ± 0.48 1.13 ± 0.51 .33
MEA QRS () 60 (−99-90) 63 (−99-90) .93
QTc (ms) 204 ± 19 204 ± 16 .98
Echocardiography
LA/Ao 1.3 (1-2.6) 1.22 (0.9-1.8) .15
LVDDn 1.5 ± 0.1 1.5 ± 0.2 .72
LVDSn 1.0 (0.6–1.6) 1.0 (0.6-1.3) .03
FS (%) 27 ± 9 30 ± 7 .002
EPSSn 1.92 (0.47-7.1) 1.3 (0.41-2.32) .001
E-wave
velocity (cm/s)
59 ± 15 66 ± 13 .009
A-wave
velocity (cm/s)
47 ± 14 54 ± 13 .002
MPI 0.56 ± 0.24 0.55 ± 0.16 .82
EDVi (mL/m2) 62 (28–101) 60 (32-87) .026
ESVi (mL/m2) 34 ± 12 29 ± 10 .10
EF (%) 48 ± 11 51 ± 10 .35
Note: Normally and nonnormally distributed data are expressed as mean
± standard deviation and median and range (minimum–maximum),
respectively. Values with statistically significant difference are indicated
in bold.
Abbreviations: EDVi, end diastolic volume indexed to body surface area;
EF, ejection fraction; EPSSn, E-point-to-septal separation normalized to
body weight; ESVi, end systolic volume indexed to body surface area;
FS, fractional shortening; HR, heart rate; LVDDn, left ventricular diastolic
diameter normalized to body weight; LVDSn, left ventricular systolic
diameter normalized to body weight; MEA, mean electrical axis; MPI,
myocardial performance index; QTc, QT corrected for heart rate, LA/Ao,
left atrial to aortic root ratio.
GUGLIELMINI ET AL. 1939
index of the global myocardial function combining both systolic and dia-
stolic cardiac performance. The principal findings were that hypothyroid
dogs had mild ECG and echocardiographic changes compared to clinically
healthy dogs, and these cardiac changes improved after levothyroxine
supplementation. Furthermore, the MPI was not significantly different
neither between hypothyroid dogs at the time of diagnosis and control
dogs nor in the former dogs before and after approximately 2 months of
treatment. Although the effect of thyroid hormones on cardiac function
has been investigated previously in dogs,8,9 ours is the first study com-
paring hypothyroid dogs with a control group of clinically healthy dogs.
The differential diagnosis of a dilated and hypokinetic LV is chal-
lenging in the dog, and the final diagnosis often can be achieved only
by postmortem evaluation of the heart.15 Therefore, evaluation of
thyroid function has been suggested in the diagnostic evaluation to
rule out hypothyroidism-induced cardiomyopathy.15 Based on our
results, this assumption likely should be reconsidered. Our findings
are similar to those of a recent study focused on the evaluation of
the relationship between hypothyroidism and DCM in Doberman
Pinschers.33 In that study, a cause-effect relationship between the
2 diseases could not be identified, and the authors stated that hypo-
thyroidism does not play any role in the etiology and progression of
DCM.33 Similarly, results of our study do not justify considering
hypothyroid-induced cardiac changes as identical to DCM, because
the observed echocardiographic changes were too mild to reflect clini-
cally relevant cardiac dysfunction. Some isolated reports of dogs with
clinically relevant cardiac dysfunction associated with hypothyroidism
have been published previously.3-6 However, these cases were only
sporadic compared to the overall prevalence of hypothyroidism in
dogs.34 It also must be considered that the diagnosis of hypothyroid-
ism in dogs is often challenging, and the risk of misdiagnosing hypo-
thyroidism in dogs with non-thyroidal illness syndrome is a major
concern.1,33,34 Dogs enrolled in our study represented a large cohort of
hypothyroid dogs that were managed identically. In particular, all dogs
underwent a standardized diagnostic protocol and all questionable
cases received a rhTSH-stimulation test to obtain a definitive diagno-
sis.22 Therefore, all dogs in our study had an ascertained diagnosis, but
none of them showed clinical signs of cardiac disease nor had clinically
relevant cardiac changes detected on ECG and echocardiography.
When systematically considering the measured ECG variables,
mean HR was significantly decreased in the hypothyroid dogs at T0
compared to that of the control group, but only 1 hypothyroid dogs was
bradycardic. Decreased HR in dogs with spontaneous and experimentally
induced hypothyroidism has been reported,7,9,11,12 and may be caused
by a direct effect of thyroid hormones on the myocardium, decrease in
tissue oxygen consumption, or downregulation of β-adrenergic receptors
causing a decreased response to sympathetic stimulation.35 The P- and
R-wave amplitudes also were significantly decreased in the hypothyroid
group compared to those of the control group. In 2 previous studies, low
R-waves were reported in 11 of 19 (58%) and in 24 of 66 (36%) of hypo-
thyroid dogs.8,9 Although the exact cause of low R-wave amplitude is
not known, obesity, decreased myocardial mass, or decreased circulating
blood volume associated with hypothyroidism may be responsible for
this ECG modification.35 Finally, a significantly lower MEA of the QRS
between hypothyroid dogs and the control group was noted. Changes
in the MEA of the QRS may indicate ventricular chamber enlargement
or intraventricular conduction disturbances,23 and only 1 previous
study reported a slight deviation in the MEA of the QRS in 3 hypothy-
roid dogs.11 However, after reviewing each ECG, we noted that 1 dog
had a left axis deviation (ie, MEA = −11; reference range, +40 to
+110) that normalized after treatment, suggesting a transient intraven-
tricular conduction disturbance that resolved after hormone supple-
mentation. Another dog had a permanent right bundle branch block,
with calculated MEA of the QRS of −99. This case alone might be
responsible for the observed shifting of the median MEA of the QRS of
the entire hypothyroid group.
Regarding the left-sided echocardiographic linear measurements
and derivate indices, a few hypothyroid dogs had slightly increased
LA/Ao and LVDSn (5 dogs and 1 dog, respectively), but the median
values were not significantly different compared to those of clinically
healthy dogs. Although previous studies documented increased LA
and LV dimensions in dogs with hypothyroidism,5,8 our results showed
that cardiac remodeling with left-sided cardiac enlargement is not a
consistent finding in the overall population of hypothyroid dogs.
Moreover, when comparing hypothyroid dogs at T0 and T60, 2 dogs
maintained an LA/Ao above the reference limit, and only 1 dog
showed an LVDSn value equal to 1.3. These findings suggest that
even mild left-sided cardiac dilatation tends to normalize after appro-
priate hormone replacement, as observed in other studies.6,8 Among
the echocardiographic indices of LV systolic function, only EPSSn was
significantly increased in hypothyroid dogs compared to control dogs,
whereas both EPSSn and FS improved after treatment in dogs with
hypothyroidism. These findings may reflect a mild negative inotropic
effect induced by the absence of an adequate concentrations of thy-
roid hormones or, conversely, a positive inotropic effect of hormone
replacement.5,8,36 The transmitral E-wave velocity was significantly
decreased in hypothyroid dogs at T0 compared to the control group,
whereas a significant increase was seen after levothyroxine treatment
for both E- and A-wave velocities. Because no significant differences
in LA/Ao and LVDDn were observed between the groups, suggesting
unchanged LV preload, the observed changes in transmitral blood flow
velocities might be explained by slight impairment in LV diastolic func-
tion in hypothyroid dogs at T0. On the other hand, increases in E- and
A- wave velocities at T60 more likely may be secondary to an increase
in HR than an indication of LV diastolic dysfunction.37
No significant difference was found in the mean MPI between
hypothyroid dogs at T0 and the control group and between T0 and
T60 in hypothyroid dogs. Clinical application of the MPI in dogs
includes evaluation of the global ventricular function of the LV, right
ventricle or both in Newfoundland dogs with DCM, Boxer dogs with
arrhythmogenic right ventricular cardiomyopathy, and in dogs with
parvovirus infection, myxomatous mitral valve disease (MMVD), tri-
cuspid regurgitation, or pulmonary arterial hypertension.38-45 These
studies showed a significant increase in the LV MPI in dogs with
symptomatic MMVD compared to control dogs and dogs with asymp-
tomatic MMVD,40 as well as in Newfoundland dogs with DCM
compared to clinically healthy Newfoundland dogs,38 whereas no
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difference was found in Boxer dogs with or without arrhythmogenic
right ventricular cardiomyopathy.43,44 Furthermore, an increased LV
and right ventricular MPI had negative prognostic value in dogs with
parvovirus infection45 and in dogs with MMVD,42 respectively. Our
results suggest that MPI has poor diagnostic usefulness in identifying
either the subtle cardiac changes induced by hypothyroidism or the
positive changes of levothyroxine supplementation. These findings
are in contrast with those in humans with hypothyroidism, in whom
measurement of MPI allowed identification of deterioration in cardiac
function that was reversible after levothyroxine replacement.17,20
Our study had some limitations. First, it was a 2-center study and
data were obtained by 2 independent observers (H.P. and M.B.T.)
using different ECG and ultrasound machines, as well as laboratory
instruments. However, all of the echocardiographic and ECG data
were reviewed by a single board-certified cardiologist (M.B.T.) and the
previously calculated coefficient of variation of the echocardiographic
measurements for the 2 observers was low or very low (ie, 5%-15%
and <5%, respectively). Furthermore, diagnostic and therapeutic pro-
tocols for hypothyroidism were standardized at the beginning of the
study. Second, the echocardiographic assessment of the cardiac func-
tion was based only on conventional echocardiographic techniques,
and no advanced techniques (eg, tissue Doppler imaging, speckle
tracking) were used. These latter techniques are more sensitive to
detect subtle changes of systolic or diastolic cardiac function, as
recently demonstrated in dogs with other endocrine diseases such as
diabetes mellitus and hyperadrenocorticism.46,47 Thus, it cannot be
completely excluded that any minor changes in cardiac function in the
hypothyroid dogs could have been detected using advanced echocar-
diographic techniques. Finally, the time interval between the visits at
T0 and T60 of hypothyroid dogs was not constant, mainly because of
owner needs. Thus, a possible effect on the evaluated cardiac function
after hormonal replacement cannot be completely excluded.
5 | CONCLUSIONS
Our results confirmed that hypothyroidism can induce some modifica-
tions of the electromechanical cardiac function in affected dogs, but
these are usually mild and rapidly reversible after levothyroxine sup-
plementation. None of the hypothyroid dogs showed clinical signs of
heart disease as well as echocardiographic features mimicking a DCM
phenotype. Finally, MPI, an echocardiographic index of combined
systolic and diastolic function, does not seem to be a useful clinical
variable to identify cardiac dysfunction in dogs with spontaneous
hypothyroidism.
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